Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown
to provide modest improvements in lung function in patients with
mild-to-moderate asthma, but its efficacy in patients with
moderate-to-severe asthma has not been assessed. Authors hypothesized that
this drug might provide benefit if combined with montelukast, a
leukotriene receptor antagonist, in patients whose symptoms are
uncontrolled by inhaled corticosteroids and long-acting β-agonists.
The combination of roflumilast with montelukast compared with
montelukast alone improved lung function and asthma control in patients
with moderate-to-severe asthma and deserves further study for this
indication.
Free full text:
No comments:
Post a Comment